drugset / Trial / NCT07278479

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

NCT07278479 ↗

Phase 1/2 Recruiting 138 enrolled Molecular Partners AG Orano Med LLC · collab
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

Timeline

Start
2026-05-18
Primary completion
2028-09
Completion
2032-09

Drugs

EvaluationDrugModalityDoseRoute
Subject [212Pb]Pb-MP0712 Unknown — —